7 December 2004
30 November 2004
9 November 2004
25 October 2004
6 October 2004
21 September 2004
14 September 2004
14 September 2004
10 June 2004
26 May 2004
10 May 2004
6 April 2004
5 April 2004
4 February 2004
ING pharma conference
30 November 2004
General presentation
9 November 2004
CSFB 5th Annual European Large Cap Pharma Conference
Mike Rance (VP, Corporate Affairs) - (PDF 505 kb)
Nigel Doran (Global Brand Director, Seroquel) - (PDF 1,916 kb)
25 October 2004
Restatement of financial figures
Restated IAS / IFRS figures - (PDF 205 kb)
Analyst presentation - (PDF 130 kb)
6 October 2004
Annual Business Review
Press Release and Pipeline table
R&D Pipeline Summary - (PDF 56 kb)
Presentations
Discovery/Early Pipeline - (PDF 2,022 kb)
Cardiovascular - (PDF 2,433 kb)
Emerging Markets - (PDF 2,333 kb)
21 September 2004
Merrill Lynch Global Drug, Biotech & Medical Devices Conference
14 September 2004
Bear Stearns Pharma Conference
14 September 2004
IFRS Conference
10 June 2004
Goldman Sachs Healthcare Conference, California
26 May 2004
HSBC SRI briefing, London
10 May 2004
Exane Pharma Conference, Paris
6 April 2004
Manufacturing telecon with Goldman Sachs
5 April 2004
CDC Ixis Cancer Seminar, Paris
4 February 2004
Merrill Lynch Conference 2004, New York
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:34 GMT
Detailed share priceStock symbol - AZN
On LSE, NYSE and OMX
Introduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
